Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**HT61** is a small quinolone-derived compound (molecular mass ~400 Da) with bactericidal activity against gram-positive bacteria, including methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* (MSSA and MRSA), particularly effective against non-multiplying cells and biofilms. It acts as a membrane-active antimicrobial by partitioning into the negatively charged bacterial lipid bilayer due to its cationic charge, causing structural disruption, membrane depolarization, loss of integrity, ATP leakage, and eventual cell lysis. HT61 demonstrates synergy with aminoglycosides (e.g., neomycin, gentamicin, tobramycin) and antiseptics (e.g., chlorhexidine, mupirocin), enhancing their efficacy against *S. aureus* and tobramycin-resistant *Pseudomonas aeruginosa* strains in vitro, in biofilms, and in murine models of skin and pulmonary infections, though it shows limited direct activity alone against gram-negative bacteria.[1][2][3][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HT61.